Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal

Lead Drug Felzartamab Is Pipeline-In-A-Product

May 22 2024

• By Mandy Jackson

Isometric Business Success Concept. Entrepreneur business man leader. Searching for opportunities. — Biogen's HI-Bio buy merges immunology and rare disease capabilities • Source: Shutterstock

Related Content

Novartis Aims To Fly High In Kidney Disease With Chinook Buy

Jun 12 2023

Finance Watch: Three New Funds Bring $1.6bn-Plus For Biopharma Firms Globally

Jan 04 2024

Biogen’s Singhal Offers A Look Into Company's Pipeline Review

Feb 09 2024

Biogen Sees Improving Momentum In Slow Leqembi Launch

Apr 24 2024

Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence

Apr 11 2024

With $120m, HI-Bio Aims To Rapidly Prove Approach To Immune-Mediated Diseases

Nov 03 2022

As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal

Jun 15 2022

Related Companies

Biogen, Inc.

Human Immunology Biosciences, Inc.

MorphoSys AG

Graphite Bio, Inc.

Arsenal Biosciences, Inc.

Genentech, Inc.

UCB S.A.

Johnson & Johnson

Vertex Pharmaceuticals Incorporated

Alpine Immune Sciences Inc.

Novartis AG

Chinook Therapeutics, Inc.

Additional Topics

Deals M & A Strategy Business Strategies Commercial Immune Disorders BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.